PharmTech News

Articles

The second part of the CPhI Annual Report has predicted an accelerated rate of change in pharma manufacturing and supply over the coming five years.

CPhI Report Predicts Accelerated Rate of Change in Pharma Manufacturing and Supply Over Next Five Years

The $3 million investment will go towards various projects investigating key product attributes for therapeutic proteins.

NIIMBL Invests $3 Million in Six Biopharmaceutical Manufacturing Products

The first part of the 2021 CPhI Annual Report has been published and predicts a strong outlook for CDMOs over the next few years.

CPhI Reports Strong Outlook for Outsourced Services in Near Future

Executives that participated in the CPhI post-pandemic survey are predicting a push for repatriation of manufacturing globally.

CPhI Post-Pandemic Survey Suggests Drive for Repatriation of Manufacturing

CPhI’s post-pandemic report predicts strong progression in pharma innovation, with breakthroughs in multi-modal disease therapies, a transformative effect of mRNA platforms, and significant growth in contract services.

CPhI Report Predicts Strong Growth in Contract Services

CPhI China event organizers are encouraged by the success of the recent event and claim that it demonstrates a reassuring return to form for pharma events in 2021, which will also fuel a boom for the industry.

CPhI China Success Provides Encouragement for 2021 Events and Boon for Industry

The CPhI event, which was originally scheduled for Aug. 31–Sept. 2, 2021 at the Fiera Milano in Milan, Italy, will be rescheduled for Nov. 9–11, 2021 at the same venue.

CPhI Worldwide Moves to November 2021

Analysis from the CPhI Annual Report has revealed that the global contract services sector is benefitting from a switch toward COVID-19 manufacturing and clinical-stage contracts; however, mega-cap pharma innovation is slowing outsourcing.

CPhI Annual Report Reveals that COVID-19 is Benefitting CDMOs 

The third part of the CPhI annual report has predicted a significant amount of pressure will be placed on bioprocessing networks should COVID-19 biologics gain approval.

Biomanufacturing Capacity Facing Huge Pressure, Notes CPhI Annual Report

The judges chose Sheng from a shortlist of seven candidates and highlighted his work in the Taiwanese and global markets while guiding the company through “pivotal changes” that demonstrated his abilities as a “top CEO.”

CPhI News